AsianScientist (Dec. 19, 2013) – Sihuan Pharmaceutical Holdings Group has signed an agreement with to-BBB technologies B.V. to combine its drug compounds and to-BBB’s G-Technology for a research study.
to-BBB, headquartered in Leiden, the Netherlands, is engaged in the development of brain-targeted drug delivery technologies and products, called “G-Technology.”
G-Technology enhances the delivery of drugs to across the blood-brain barrier in a safe manner for the treatment of central nervous system (CNS) related diseases. This technique has obtained multiple pre-clinical and clinical validations, including the developmental compound 2B3-101 in Phase IIa trial in France, Belgium and Netherland for the treatment of brain cancers.
——
Source: Sihuan Pharmaceutical Holdings Group.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.